Figitumumab

Figitumumab (previously CP-751871) is a monoclonal antibody^[1] targeting the insulin-like growth factor-1 receptor being investigated for the treatment of various types of cancer, for example adrenocortical carcinoma^[2] and non-small cell lung cancer (NSCLC)^[3].

This drug is being developed by Pfizer.

Anti-cancer mechanism

See Insulin-like growth factor 1 receptor role in cancer.

Clinical trials

The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths^[4] but others continue^[5][6].

It will be included in the forthcoming I-SPY2 breast cancer trial.^[7]

References

1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
2. ^ Haluska, P; Worden, F; Olmos, D; Yin, D; Schteingart, D; Batzel, GN; Paccagnella, ML; De Bono, JS et al. (2009). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma". Cancer chemotherapy and pharmacology 65 (4): 765–773. doi:10.1007/s00280-009-1083-9. PMC 2875253. PMID 19649631. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2875253. 
3. ^ Gualberto, A; Karp, DD (2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical lung cancer 10 (4): 273–80. doi:10.3816/CLC.2009.n.038. PMID 19632947. 
4. ^ Krauskopf, Lewis (29 December 2009). "Pfizer ends late-stage lung-cancer study". Reuters. http://www.reuters.com/article/idUSTRE5BS3XY20091229. 
5. ^ ClinicalTrials.gov NCT00976508 Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
6. ^ ClinicalTrials.gov NCT00635245 CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery
7. ^ "Breast cancer study aims to speed drugs, cooperation". Reuters. March 2010. http://www.reuters.com/article/idUSN1612347120100317.